This site is intended for healthcare professionals only
This site is intended for healthcare professionals only
LMU Hospital, Munich, Germany
Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches like inhibitors of the B-cell receptor pathway and immunological approaches.
Professor Dreyling is coordinator of the European MCL Network and president elect of the German Lymphoma Alliance. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals.
Ospedale SS Antonio e Biagio, Alessandria, Italy
Marco Ladetto is Head of the Hematology Division at “Ospedale SS Antonio e Biagio” in Alessandria, Italy and Assistant Professor in Hematology at the University of Torino. He studied medicine at the University of Torino and, after obtaining his post-graduate degree in hematology, went on to work at the Dana Farber Cancer Institute in Boston.Professor Ladetto’s main fields of interest are the diagnosis, prognosis and treatment of lymphoma, myeloma and chronic lymphocytic leukemia, minimal residual disease and other biological prognostic factors in mature lymphoid tumors. He is actively involved in the design of clinical trials in the context of Fondazione Italiana and the European Mantle Cell Lymphoma Network.
Professor Ladetto has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals. He is a member of the Euro-MRD network, past head of the “Biological Studies Committee” and current member of the Directive Board of Fondazione Italiana Linfomi (FIL). He has also been subject editor for the Lymphoma Guidelines of the European Society of Medical Oncology, and he is currently a member of the European Hematology Association Clinical Guidelines Committee.
Nottingham University Hospitals
Dr Chris Fox is a Consultant Hematologist at Nottingham University Hospitals, where he is the lead clinician for lymphoma and the clinical lead for Hematology research. He is an Honorary Associate Professor at the University of Nottingham. His main research interests focus on the aggressive lymphomas, including central nervous system and T cell lymphoma.
Dr Fox Chairs the UK aggressive lymphoma sub-group of the National Cancer Research Institute (NCRI) and is a steering committee member for the UK TAP (therapy accelerated programme) network of early phase blood cancer trials. He has co-authored research papers in high-impact journals including Blood, Journal of Clinical Oncology, Clinical Cancer Research, JAMA Oncology, Haematologica and Lancet Haematology.
Lund University, Sweden
Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. Professor Jerkeman is also Chairman of the Nordic Lymphoma Group and the National Guidelines for Lymphoma, Sweden. His research focuses on improving the quality of life and survival of patients with malignant lymphomas. He completed his doctoral training at Lund University, Sweden.
Professor Jerkeman is the Coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma, and has also served as coordinator of the Swedish Lymphoma Register for many years. He is an Editor of the European Society of Medical Oncology Guidelines and a member of the American Society of Hematology. He has over 120 publications in peer-reviewed journals.
Gene Center, Munich, Germany
Marion Subklewe is Head of the Laboratory for Translational Cancer Immunotherapy at the Gene Center, Munich and Professor of Internal Medicine at Ludwig Maximilian University of Munich, Germany. She studied medicine at University Hospital Tübingen and completed her postdoctoral fellowship at Rockefeller University in New York.
Professor Subklewe is current Head of the Immunotherapy Program in Haematology and the CAR T Program at University Hospital Munich, Founder and Speaker of the national “Harmonize MRD Flow” Consortium and member of the ELN Working group on MRD. She is also active in clinical research and has been Principal Investigator in 3 I-IT trials in AML and ALL, as well as in over 30 oligo- and multicentric Phase I trials in leukaemia and lymphoma. In recognition of her work, Professor Subklewe has received numerous honours and awards including the EHA Educational Presentation and ASH Abstract Achievement Awards.
LMU Hospital, Munich, Germany
Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches like inhibitors of the B-cell receptor pathway and immunological approaches.
Professor Dreyling is coordinator of the European MCL Network and president elect of the German Lymphoma Alliance. He has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals.
Ospedale SS Antonio e Biagio, Alessandria, Italy
Marco Ladetto is Head of the Hematology Division at “Ospedale SS Antonio e Biagio” in Alessandria, Italy and Assistant Professor in Hematology at the University of Torino. He studied medicine at the University of Torino and, after obtaining his post-graduate degree in hematology, went on to work at the Dana Farber Cancer Institute in Boston.Professor Ladetto’s main fields of interest are the diagnosis, prognosis and treatment of lymphoma, myeloma and chronic lymphocytic leukemia, minimal residual disease and other biological prognostic factors in mature lymphoid tumors. He is actively involved in the design of clinical trials in the context of Fondazione Italiana and the European Mantle Cell Lymphoma Network.
Professor Ladetto has co-authored numerous scientific papers, book chapters and abstracts in international peer-reviewed journals. He is a member of the Euro-MRD network, past head of the “Biological Studies Committee” and current member of the Directive Board of Fondazione Italiana Linfomi (FIL). He has also been subject editor for the Lymphoma Guidelines of the European Society of Medical Oncology, and he is currently a member of the European Hematology Association Clinical Guidelines Committee.
Nottingham University Hospitals
Dr Chris Fox is a Consultant Hematologist at Nottingham University Hospitals, where he is the lead clinician for lymphoma and the clinical lead for Hematology research. He is an Honorary Associate Professor at the University of Nottingham. His main research interests focus on the aggressive lymphomas, including central nervous system and T cell lymphoma.
Dr Fox Chairs the UK aggressive lymphoma sub-group of the National Cancer Research Institute (NCRI) and is a steering committee member for the UK TAP (therapy accelerated programme) network of early phase blood cancer trials. He has co-authored research papers in high-impact journals including Blood, Journal of Clinical Oncology, Clinical Cancer Research, JAMA Oncology, Haematologica and Lancet Haematology.
Lund University, Sweden
Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. Professor Jerkeman is also Chairman of the Nordic Lymphoma Group and the National Guidelines for Lymphoma, Sweden. His research focuses on improving the quality of life and survival of patients with malignant lymphomas. He completed his doctoral training at Lund University, Sweden.
Professor Jerkeman is the Coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma, and has also served as coordinator of the Swedish Lymphoma Register for many years. He is an Editor of the European Society of Medical Oncology Guidelines and a member of the American Society of Hematology. He has over 120 publications in peer-reviewed journals.
Gene Center, Munich, Germany
Marion Subklewe is Head of the Laboratory for Translational Cancer Immunotherapy at the Gene Center, Munich and Professor of Internal Medicine at Ludwig Maximilian University of Munich, Germany. She studied medicine at University Hospital Tübingen and completed her postdoctoral fellowship at Rockefeller University in New York.
Professor Subklewe is current Head of the Immunotherapy Program in Haematology and the CAR T Program at University Hospital Munich, Founder and Speaker of the national “Harmonize MRD Flow” Consortium and member of the ELN Working group on MRD. She is also active in clinical research and has been Principal Investigator in 3 I-IT trials in AML and ALL, as well as in over 30 oligo- and multicentric Phase I trials in leukaemia and lymphoma. In recognition of her work, Professor Subklewe has received numerous honours and awards including the EHA Educational Presentation and ASH Abstract Achievement Awards.
